# Researcher → Verifier Handoff — VERDICT (vrf-handoff-2026-06-05-001) — FDA 503A Peptide Dossier

> Source dossier: `03 Projects/Researcher/dossiers/fda_503a_peptides.md`
> Audit run id: `vrd-fda-503a-2026-06-05-001`
> Audit log id: `aud-2026-06-05-001`
> Verdict (dossier-level): **PASS at 0.94**
> Per-claim verdicts: 8 PASS (weighted scores 0.815–0.965; mean 0.93)
> Temperature: 0.0
> Routed to: researcher (claim promotion) + mavis (Scribe dispatch)

## Lane summary (for Mavis/Scribe routing)

The FDA 503A peptide dossier has been audited and is **verified at the dossier level** (PASS 0.94) and per-claim (8 PASS). The dossier is eligible to flow into the Scribe lane on Mavis dispatch.

### Recommended next action

- **For Mavis (operator):** consume the Verifier handoff. On dispatch, spawn the Scribe to render from `03 Projects/Researcher/dossiers/fda_503a_peptides.md`.
- **For Scribe (downstream, out of scope for this Verifier run):** the 7/12/13 number family must be carried forward explicitly in the rendered output to prevent downstream confusion. The 2 ADJUDICATE decisions (docket-number, meeting-time) should be referenced in the source-trail so a reader does not get confused by the FDA-2026-N-2979 reference on the FDA meeting page.

### Watch-items preserved in dossier (re-verify triggers)

1. After July 23-24, 2026: re-fetch FDA's PCAC outcomes and update dossier.
2. When FDA publishes the second-meeting notice (before end of February 2027): update clm-2026-06-05-008 to primary-source registration.
3. On any FDA action that extends enforcement discretion to one or more of the 12 peptides: high-priority re-verification of clm-2026-06-05-006.
4. On the next REFRESH: re-fetch `fda.gov/media/94155/download` via a PDF parser (pdftotext, pdf2text) to upgrade clm-2026-06-05-007 from secondary-corroborated (0.92) to primary-sourced (~0.99).
5. Watch the docket for additional public comments (currently 65 received as of 2026-06-05 10:25 CT).

## Per-claim verdicts (8)

| Claim | Verdict | Score | Issue |
|---|---|---|---|
| clm-2026-06-05-001 (FR notice 91 FR 20465 headline) | PASS | 0.965 | 3-way corroboration: FR, FDA meeting page, Regulations.gov all cite FDA-2025-N-6895. The 2026-N-2979 reference is a copy-paste typo on the FDA meeting page Instructions paragraph (adjudicated). |
| clm-2026-06-05-002 (per-day times + location) | PASS | 0.965 | FR DATES section verbatim: July 23 8am-4:30pm ET; July 24 8am-3:50pm ET. FDA meeting page top-line 8am-3:50pm ET is a UI simplification (adjudicated). |
| clm-2026-06-05-003 (July 23 agenda, 4 peptides) | PASS | 0.965 | FR verbatim corroborates BPC-157, KPV, TB-500, MOTs-C with uses-evaluated table. |
| clm-2026-06-05-004 (July 24 agenda, 3 peptides) | PASS | 0.965 | FR verbatim corroborates Emideltide/DSIP, Semax, Epitalon with uses-evaluated table. |
| clm-2026-06-05-005 (inclusion on 503A Bulks List framing) | PASS | 0.965 | FR verbatim: "inclusion on the 503A Bulks List". Correctly distinguished from Cat 1 placement. |
| clm-2026-06-05-006 (Removal from Cat 2 ≠ 503A bulks list ≠ Cat 1) | PASS | 0.965 | FDA 503A bulks hub verbatim: "FDA does not intend to take action against a compounder for compounding drugs using bulk drug substances listed in category 1". Frier Levitt and Orrick both confirm. 3-way corroboration. |
| clm-2026-06-05-007 (12-peptide Cat 2 removal enumeration) | PASS | 0.830 | 12-name enumeration is secondary-corroborated across Frier Levitt (verbatim) + Orrick (count-only). 7-of-12 names indirectly primary-verified via FR notice. Primary PDF (`fda.gov/media/94155/download`) returns as raw binary — Verifier independently confirmed the edge case. Weight 0.92 is correct discipline. |
| clm-2026-06-05-008 (second PCAC meeting before end of Feb 2027) | PASS | 0.815 | Forward-looking schedule claim; Frier Levitt + Orrick both list the 5 not-on-July + GHK-Cu non-injectable. No primary PCAC meeting notice yet exists (FDA must publish by Feb 2027). Weight 0.85 is correct discipline. |
| dossiers/fda_503a_peptides.md (dossier-level) | **PASS** | **0.940** | All 8 per-claim PASS. 7/12/13 number family correctly preserved. 2 contradictions adjudicated. Stage discipline end-to-end. PDF-as-binary edge case correctly handled. |

## ADJUDICATE decisions (2)

### Decision 2026-06-05-001: Docket-number inconsistency (FDA-2025-N-6895 vs FDA-2026-N-2979)
- **Outcome:** Uphold Researcher's inference. **FDA-2025-N-6895 is authoritative.** The FDA-2026-N-2979 reference on the FDA meeting page Instructions paragraph is a copy-paste typo, not a parallel docket. Weight on FDA-2025-N-6895: 0.99.
- **Written to:** `decisions/2026-06-05-001-docket-number.md`.

### Decision 2026-06-05-002: Meeting-time inconsistency (FR per-day times vs FDA meeting page top-line)
- **Outcome:** Uphold Researcher's inference. **FR per-day times are authoritative** (July 23: 8am-4:30pm ET; July 24: 8am-3:50pm ET). The FDA meeting page top-line 8am-3:50pm ET is a UI simplification. Weight on FR per-day times: 0.99.
- **Written to:** `decisions/2026-06-05-002-meeting-time.md`.

## Files (verifier-side)

- Verdicts: `knowledge/verdicts.jsonl#vrd-fda-503a-2026-06-05-001` through `vrd-fda-503a-2026-06-05-009`
- Audit log: `knowledge/audit-log.jsonl#aud-2026-06-05-001`
- Findings: `knowledge/findings.jsonl#fnd-2026-06-05-001` through `fnd-2026-06-05-007`
- ADJUDICATE decisions: `decisions/2026-06-05-001-docket-number.md`, `decisions/2026-06-05-002-meeting-time.md`
- Verifier raw captures: `raw/fda_regulation/2026-06-05/20260605-103000-vrf-*.json` (6 independent re-captures)
- Researcher audit dossier (updated): `dossiers/researcher-audit.md` (2026-06-05 signal appended)
- Auditor brief (updated): `notes/auditor-brief.md`
- Run receipt: `runs/RUN-20260605-1042Z.md`

## Source trail (8 claims)

- **Primary sources (4):** Federal Register 91 FR 20465 (Doc. 2026-07361); FDA Advisory Committee Calendar page (PCAC July 23-24, 2026); FDA 503A bulks hub page; Regulations.gov docket FDA-2025-N-6895.
- **Secondary sources (2):** Frier Levitt (April 16, 2026); JD Supra / Orrick, Herrington & Sutcliffe LLP (April 17, 2026).
- **Independent re-capture by Verifier:** all 6 sources re-fetched 2026-06-05 ~10:25 CT; verbatim match with Researcher's captures on all 8 claims. PDF edge case for `fda.gov/media/94155/download` independently confirmed.

## What this handoff does NOT include

- Scribe handoff (Verifier owns Scribe routing on PASS, per the parent's hard constraints).
- Mavis handoff (no Mavis-vault touch; this stays in Verifier→Researcher→Mavis lane).
- Builder handoff (no builder lane active for this dossier).
- Hermes kanban update (no kanban lane active for this dossier).
- OpenClaw bridge touch (no OpenClaw bridge activity).
- Git commit / push (per hard constraints: "no commit, no push, no external sends").

---

*Status: VERIFIED. vrf-handoff-2026-06-05-001 has been audited by Verifier. Verdict: PASS at 0.94 (dossier-level). 8 per-claim PASS. 2 ADJUDICATE decisions written. Dossier is eligible to flow into the Scribe lane on Mavis dispatch.*
